Back to Search Start Over

A truncated fragment of Ov-ASP-1 consisting of the core pathogenesis-related-1 (PR-1) domain maintains adjuvanticity as the full-length protein.

Authors :
Guo, Jingjing
Yang, Yi
Xiao, Wenjun
Sun, Weilai
Yu, Hong
Du, Lanying
Lustigman, Sara
Jiang, Shibo
Kou, Zhihua
Zhou, Yusen
Source :
Vaccine. Apr2015, Vol. 33 Issue 16, p1974-1980. 7p.
Publication Year :
2015

Abstract

The Onchocerca volvulus activation-associated secreted protein-1 ( Ov -ASP-1) has good adjuvanticity for a variety of antigens and vaccines, probably due to its ability activate antigen-processing cells (APCs). However, the functional domain of Ov -ASP-1 as an adjuvant is not clearly defined. Based on the structural prediction of this protein family, we constructed a 16-kDa recombinant protein of Ov -ASP-1 that contains only the core pathogenesis-related-1 (PR-1) domain (residues 10–153), designated ASPPR. We found that ASPPR exhibits adjuvanticity similar to that of the full-length Ov -ASP-1 (residues 10–220) for various antigens, including ovalbumin (OVA), HBsAg protein antigen, and the HIV peptide 5 (Pep5) antigen, but it is more suitable for vaccine design in ASPPR-antigen fusion proteins, and more stable in PBS than Ov -ASP-1 stored at −70 °C. These results suggest that ASPPR might be the functional region of Ov -ASP-1 as an adjuvant, and therefore could be developed as an adjuvant for human use. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
0264410X
Volume :
33
Issue :
16
Database :
Academic Search Index
Journal :
Vaccine
Publication Type :
Academic Journal
Accession number :
101917103
Full Text :
https://doi.org/10.1016/j.vaccine.2015.02.053